Differential interactions of "prosexual" drugs with 5-hydroxytryptamine1A and alpha 2-adrenergic receptors.
L L Kwong, E R Smith, J M Davidson, S J Peroutka
Behavioral Neuroscience October 1, 1986 DOI: 10.1037//0735-7044.100.5.664 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Radioligand binding study Peer reviewed |
|---|---|
| Population | Rat brain membranes |
| Interventions | 8-OH-DPAT 5-methoxy-dimethyltryptamine RDS-127 yohimbine imiloxan idazoxan |
| Citations | 38 |
| Key points | Drugs that facilitate ejaculation selectively bind to 5-HT1A receptors, while drugs that increase sexual arousal selectively bind to alpha 2-adrenergic receptors. |
Abstract
Radioligand binding studies were used to analyze the interactions of six "prosexual" drugs with 5-hydroxytryptamine1A (5-HT1A) and alpha 2-adrenergic receptors in rat brain membranes. Three drugs that facilitate seminal emissions and/or ejaculations [8-hydroxy-2-n-propylaminotetralin (8-OH-DPAT), 5-methoxy-dimethyltryptamine, and RDS-127] are potent and selective inhibitors of [3H]8-OH-DPAT binding to 5-HT1A receptors. By contrast, three drugs with primary sexual arousal effects (yohimbine, imiloxan, and idazoxan), are potent agents at alpha 2-adrenergic receptors labeled by [3H]yohimbine. These data suggest that radioligand binding analysis of prosexual agents may elucidate the pathophysiology of sexual behavior.